---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035886"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:19:07.532895+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial

## Summary
- FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.
- Net loss $55.3M vs $42.4M YoY; R&D expenses $43.1M up from $34.6M; G&A $12.6M vs $10.7M.
- Cash, equivalents, investments & restricted cash $176.4M as of June 30, 2024 (up from $135.2M Dec 31, 2023).
- Promoted Mohammed Asmal, M.D., Ph.D. to Chief Medical Officer, effective immediately; he was SVP Head of Clinical since 2022.
- Pipeline milestones: liver IND/CTA expected H2 2025–H1 2026; ocular candidate nomination for RHO-RP in 2024.

## SEC filing metadata
- accession: 0001628280-24-035886
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/0001628280-24-035886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/prme-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035886
- JSON: https://secwatch.observer/filing/0001628280-24-035886.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.